Magnesium supplementation for the management of essential hypertension in adults
Dickinson HO, Nicolson DJ, Campbell F, Cook JV, Beyer FR, Ford GA, Mason J
The Cochrane database of systematic reviews · 58 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2006-07-18 · Cochrane Database Syst Rev · vol. 2010 · número 1 · pág. CD004640
- Editorial
- Elsevier BV
- Citado
- 114 citas · más que el 95% de estudios similares · 5.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 82 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Magnesium in Health and Disease · Blood Pressure and Hypertension Studies · Sodium Intake and Health
- Palabras clave
- magnesium supplementation, essential hypertension, blood pressure reduction, systolic blood pressure, diastolic blood pressure, dietary magnesium, antihypertensive therapy, subgroup analysis, sex differences, age differences, baseline blood pressure, cardiovascular risk reduction, quality of life
- MeSH
- humans, hypertension, magnesium, blood pressure, dietary supplements, adult, randomized controlled trials as topic
7 autores
- Heather Olivia Dickinson🇬🇧Newcastle University
- Donald Nicolson🇬🇧University of Leeds
- Fiona Campbell🇬🇧University of Sheffield
- Julia V Cook🇬🇧Newcastle University
- Fiona R. Beyer🇬🇧Newcastle University
- Gary A. Ford🇬🇧Royal Victoria Infirmary
- James M. Mason🇬🇧Durham University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Epidemiological evidence on the effects of magnesium on blood pressure is inconsistent. Metabolic and experimental studies suggest that magnesium may have a role in the regulation of blood pressure.
Objectives
To evaluate the effects of magnesium supplementation as treatment for primary hypertension in adults.
Search strategy
We searched the Cochrane Library, MEDLINE, EMBASE, Science Citation Index, ISI Proceedings, ClinicalTrials.gov, Current Controlled Trials, CAB abstracts, and reference lists of systematic reviews, meta-analyses and randomised controlled trials (RCTs) included in the review.
Selection criteria
Inclusion criteria were: 1) RCTs of a parallel or crossover design comparing oral magnesium supplementation with placebo, no treatment, or usual care; 2) treatment and follow-up >/=8 weeks; 3) participants over 18 years old, with raised systolic blood pressure (SBP) >/=140 mmHg or diastolic blood pressure (DBP) >/=85 mmHg; 4) SBP and DBP reported at end of follow-up. We excluded trials where: participants were pregnant; received antihypertensive medication which changed during the study; or magnesium supplementation was combined with other interventions.
Data collection and analysis
Two reviewers independently abstracted data and assessed trial quality. Disagreements were resolved by discussion or a third reviewer. Random effects meta-analyses and sensitivity analyses were conducted.
Main results
Twelve RCTs (n=545) with eight to 26 weeks follow-up met our inclusion criteria. The results of the individual trials were heterogeneous. Combining all trials, participants receiving magnesium supplements as compared to control did not significantly reduce SBP (mean difference: -1.3 mmHg, 95% CI: -4.0 to 1.5, I(2)=67%), but did statistically significantly reduce DBP (mean difference: -2.2 mmHg, 95% CI: -3.4 to -0.9, I(2)=47%). Sensitivity analyses excluding poor quality trials yielded similar results. Sub-group analyses and meta-regression indicated that heterogeneity between trials could not be explained by dose of magnesium, baseline blood pressure or the proportion of males among the participants.
Authors' conclusions
In view of the poor quality of included trials and the heterogeneity between trials, the evidence in favour of a causal association between magnesium supplementation and blood pressure reduction is weak and is probably due to bias. This is because poor quality studies generally tend to over-estimate the effects of treatment. Larger, longer duration and better quality double-blind placebo controlled trials are needed to assess the effect of magnesium supplementation on blood pressure and cardiovascular outcomes.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.